Business
OXB honoured at 2025 CDMO Leadership Awards Europe in ‘Cell & Gene Therapy’ category
Oxford, UK – 29 October 2025: OXB (LSE: OXB), a global quality and innovation-led cell and gene therapy CDMO, today announces it has been recognised as a Champion in the ‘Cell & Gene Therapy’ category at the 2025 CDMO Leadership Awards Europe in Frankfurt. The prestigious Champion title is awarded to the highest-scoring CDMO in each category, based on direct feedback from biopharmaceutical professionals who have recently partnered with CDMOs. This recognition demonstrates OXB’s excellence in qua
About this update from Oxford Biomedica Plc
[{"type":"image","alt":"OXB","displaySize":"","headline":null,"caption":"OXB","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":159,"url":"https://media.zenfs.com/en/globenewswire.com/c14d9d68668513a9042681f5e1f388c2"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/fa8vdAQ1u36jC9pq9QpcgQ--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTIyMztjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/c14d9d68668513a9042681f5e1f388c2","width":300,"height":159}},"lazy":false},{"type":"text","content":"Oxford, UK – 29 October 2025: OXB (LSE: OXB), a global quality and innovation-led cell and gene therapy CDMO, today announces it has been recognised as a Champion in the ‘Cell & Gene Therapy’ category at the 2025 CDMO Leadership Awards Europe in Frankfurt. The prestigious Champion title is awarded to the highest-scoring CDMO in each category, based on direct feedback from biopharmaceutical professionals who have recently partnered with CDMOs.","length":455,"tagName":"p","attribs":{}},{"type":"text","content":"This recognition demonstrates OXB’s excellence in quality, innovation and service across its global network. It comes at a time of strong commercial momentum for OXB, driven by increased demand for its end-to-end CDMO services across key vector types and a growing portfolio of clients spanning all stages of development.","length":321,"tagName":"p","attribs":{}},{"type":"text","content":"Dr. Sebastien Ribault, Chief Business Officer of OXB, said: “We are honoured to receive this recognition from the CDMO Leadership Awards Europe. It reflects the trust and satisfaction of our clients and the dedication of our teams across the UK, US and France. As demand continues to grow, we remain committed to supporting our clients in delivering the next generation of transformative therapies to patients around the world.”","length":433,"tagName":"p"},{"type":"text","content":"-Ends-","length":6,"tagName":"p"},{"type":"text","content":"Enquiries: OXB:","length":63,"tagName":"p"},{"type":"text","content":"T: +44 (0) 1865 783 000 / E: [email protected]","length":47,"tagName":"p","attribs":{}},{"type":"text","content":"Sebastien Ribault, Chief Business OfficerICR Healthcare:T: +44 (0)20 3709 5700 / E: [email protected]","length":112,"tagName":"p","attribs":{}},{"type":"text","content"...